Some excerpts from the report
''The company expects an end of Phase II meeting with the FDA in the next few weeks to move INV102 into Phase III''
''The company is currently in partnering discussion with several pharmaceutical companies.'' (INV103)
"Based on sum-of-the-parts valuation, we believe Invion is substantially undervalued at the current share price of AUD 0.006. With the positive phase II data of INV102 and INV103, we have increased our valuation for the company from AUD 100 million to AUD 116 million, or AUD 9.7c per share. This represents a substantial upside from the current share price''
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
12.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $10.59M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 13.5¢ | 12.5¢ | $15.62K | 118.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 213400 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 57707 | 2 |
View Market Depth
| Last trade - 14.46pm 20/06/2025 (20 minute delay) ? |
| IVX (ASX) Chart |